Archives
-
TCAIM Controls OGDH and Mitochondrial Metabolism
2026-09-10
A 2025 Molecular Cell study identifies TCAIM as a mitochondrial DNAJC co-chaperone that selectively binds native OGDH and promotes its reduction through HSPA9 and LONP1. This mechanism links mitochondrial proteostasis to control of OGDH complex activity, carbohydrate catabolism, and broader metabolic state in cells and mice.
-
HyperScribe T7 Cy3 RNA Labeling Kit for RNAi Assays
2026-09-10
The HyperScribe T7 High Yield Cy3 RNA Labeling Kit supports tunable fluorescent RNA probe synthesis for in situ hybridization and Northern blot analysis. This article explains how Cy3-labeled probes can strengthen assay decisions when studying nanoparticle-enabled RNA interference in Bemisia tabaci.
-
Bay 11-7085: NF-κB Activation Assay Guide
2026-09-09
Bay 11-7085 is a practical NF-κB activation inhibitor for connecting inflammatory signaling with cell-cycle arrest and apoptosis. This guide translates its TNFα-responsive mechanism into reproducible cell assays and shows how to interpret findings in endometriosis, neuroinflammation, and infection models without overclaiming pathway specificity.
-
Niclosamide: Practical STAT3 Assay Workflows
2026-09-09
Build more informative cancer research experiments with Niclosamide by pairing STAT3 Tyr-705 measurements with apoptosis and cell-cycle readouts. A field-trial study on molluscicide safety also offers a useful framework for exposure controls, differential sensitivity, and translational limits without implying that the compound was tested in that ecological model.
-
Cisapride in iPSC Cardiotoxicity Screening
2026-09-08
Cisapride (R 51619) offers a powerful dual-perturbation model for connecting 5-HT4 receptor signaling pathway activity with hERG channel inhibition. This article presents an assay-design framework that integrates cisapride pharmacology, iPSC-cardiomyocyte phenotyping, electrophysiology, and deep-learning analysis.
-
Humanized Mice Improve CES Prodrug PK Prediction
2026-09-08
This 2025 study shows that humanized-liver mice can reduce species-related uncertainty when evaluating the carboxylesterase prodrug HD56 and its active metabolite HD561. By combining transport, enzyme-phenotyping, microsomal, plasma, and pharmacokinetic experiments, the authors established a strong in vivo–in vitro correlation that supports more human-relevant preclinical assessment of ester prodrugs.
-
Norovirus Co-opts NINJ1 for Selective Secretion
2026-09-07
Song and colleagues show that murine norovirus uses NINJ1-mediated membrane rupture as a selective route for releasing the viral protein NS1, rather than relying only on nonspecific cellular leakage. Their combination of CRISPR screening, caspase-3 perturbation, protein-interaction analysis, mutagenesis, and mouse infection experiments identifies a mechanistic link between viral protein processing, NINJ1 recruitment, and intestinal infection.
-
Mitomycin C Workflows for Cancer Research
2026-09-07
Mitomycin C combines direct DNA damage with strong experimental utility in apoptosis, sensitization, and tumor-cell proliferation assays. This guide shows how to build reproducible dose–response workflows, connect DNA replication inhibition with immune-oncology readouts, and troubleshoot solubility, timing, and interpretation problems.
-
Dextrose for Tumor Immunometabolism Workflows
2026-09-05
Use Dextrose (D-glucose) as a controlled carbon input to model nutrient competition, hypoxia adaptation, and immune-cell dysfunction in tumor microenvironment assays. This workflow combines practical concentration design, oxygen control, and troubleshooting for more reproducible glucose metabolism research.
-
Morin: Podocyte Energy Metabolism and Assay Design
2026-09-04
Morin is a natural flavonoid that links oxidative-stress biology with a newly defined AMPD2–mitochondrial energy pathway in fructose-associated podocyte injury. This guide translates the evidence into practical assay-selection, controls, and interpretation strategies.
-
EZ Cap™ EPO mRNA for Targeted Neurorepair
2026-09-04
EZ Cap™ EPO mRNA combines a Cap 1 structure, pseudouridine, and a poly(A) tail for controlled mammalian protein-expression experiments. This article translates a targeted EPO mRNA nanoparticle study into practical workflows for erythropoiesis, neuroprotection, wound-healing, and delivery research.
-
N1-Methylpseudouridine: Reliable mRNA Assays
2026-09-03
Learn how N1-Methylpseudouridine, SKU B8340, can reduce translation-related variability when researchers evaluate cell viability, proliferation, or cytotoxicity after mRNA delivery. This scenario-based guide connects formulation, controls, storage, and data interpretation to practical laboratory decisions.
-
N1-Methyl-Pseudouridine-5'-Triphosphate in Cell Assays
2026-09-03
A scenario-based guide to using N1-Methyl-Pseudouridine-5'-Triphosphate (SKU B8049) in modified-RNA workflows that support cell viability, proliferation, and cytotoxicity studies. It connects reagent specifications, in vitro transcription controls, translation evidence, assay design, and practical vendor selection.
-
Notch1–YY1–ICAM1 Axis in HCC Immunotherapy
2026-09-02
The reference study identifies the Notch1–YY1–ICAM1 pathway as a molecular determinant of immunotherapy response in hepatocellular carcinoma (HCC). Its data connect pathway disruption with stronger CD8+ T-cell cytotoxicity and granzyme-driven pyroptosis, supporting downstream targeting of YY1 as a potentially safer complement to immune checkpoint blockade.
-
ASB3 Targets MAVS to Suppress Antiviral Immunity
2026-09-02
The reference study identifies ASB3 as an E3 ubiquitin ligase that weakens antiviral innate immunity by directing K48-linked ubiquitination and proteasomal degradation of MAVS. Its gain-of-function, loss-of-function, infection, and animal experiments connect ASB3 activity to reduced interferon signaling and greater susceptibility to influenza A virus, providing a mechanistic framework for studying host regulation of RIG-I-like receptor pathways.